Synaptogenix Inc (SNPX)

[doingmybest]

Antti, excellent post with the real bottom line here. The P2b data will tell the tale whether there is a real future for bryostatin or not, everything else is either interesting or not. I find comparing bryostatin to the Anavex lead compound not interesting because neither one yet has sufficient comparative anything other than some interesting scientific theory.

NTRP mgmt. makes bold statements, which may or may not be proven correct. That opinion has to be severely discounted for multiple reasons. Bottom line is what Antti stated, 150 patients will tell the tale for this development phase, then, hopefully on to the next phase.